Indian government committee calls for Johnson & Johnson to pay patients for recalled hip implants

The Central Drugs Standard Control Organization committee report suggested a base payment of about $28,300 per patient, with final totals decided individually. (Pixabay)

A panel convened by the Indian drug and medical device regulator has recommended Johnson & Johnson compensate each Indian patient that had to undergo revision surgeries or suffered adverse reactions to its metal-on-metal hip implants recalled in August 2010.

J&J’s DePuy unit recalled 93,000 ASR hip replacement systems worldwide after data emerged showing earlier-than-expected replacement surgeries following implantation, with a 12% failure rate within five years in devices designed to last for two decades.

The company would later look to spend nearly $3 billion to settle and resolve claims stemming from more than 10,000 lawsuits, and J&J abandoned sales of metal hip replacements in 2013. In India, about 4,700 procedures were performed since they were made available in 2004.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

After over a year of deliberation, the federal Central Drugs Standard Control Organization’s (CDSCO's) committee issued a 121-page report calling for a base payment of at least about $28,300 per patient, with final totals decided individually, and an extension of the company’s reimbursement program through 2025.

The ASR all-metal implant

RELATED: J&J's DePuy comes under fire for all-metal hip manufacturing in U.K.

The committee also recommended the creation of an independent government registry for tracking the usage of high-risk medical devices, analyzing performance and usage, and potentially with legal backing to issue warnings and alerts to manufacturers—as well as CDSCO guidance on effective device recall practices.

In addition, ASR patients should have their health checked every year, including routine physical follow-ups, x-rays and soft tissue imaging, as well as blood tests for levels of cobalt and chromium from the metal implant.

Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.